Biologic determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581

Journal of Clinical Oncology

Volumn 31, Issue 14, 2013, Pages 1775-1781

  Venook, Alan P ^a   Niedzwiecki, Donna ^c   Lopatin, Margarita ^b   Ye, Xing ^c   Lee, Mark ^b   Friedman, Paula N ^d   Frankel, Wendy ^e   Clark Langone, Kim ^b   Millward, Carl ^b   Shak, Steven ^b   Goldberg, Richard M ^e   Mahmoud, Najjia N ^f   Warren, Robert S ^a   Schilsky, Richard L ^d   Bertagnolli, Monica M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Genomic Health   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDRECOLOMAB; MISMATCH REPAIR PROTEIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

12 GENE RECURRENCE SCORE; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION STUDY; CANCER GRADING; COLON TUMOR; FEMALE; GENETICS; LEUKEMIA; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MISMATCH REPAIR; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; HUMANS; LEUKEMIA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS;

MLCS; MLOWN;

EID: 84879471309     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.1096     Document Type: Article

References (46)

1. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
2. Early Breast Cancer Trialists’ Cooperative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
4. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
5. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
6. Vicuna B, Benson AB 3rd: Adjuvant therapy for stage II colon cancer: Prognostic and predictive markers. J Natl Compr Canc Netw 5:927-936, 2007
7. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines for Oncology: Colon Cancer v1.2013
8. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994, 2000
9. Kelley RK, Venook AP: Prognostic and predictive markers in stage II colon cancer: Is there a role for gene expression profiling? Clin Colorectal Cancer 10:73-80, 2011
10. Gray RG, Quirke P, Handley K, et al: Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611-4619, 2011
11. Harris EI, Lewin DN, Wang HL, et al: Lymphovascular invasion in colorectal cancer: An interobserver variability study. Am J Surg Pathol 32:1816-1821, 2008
12. O’Connell MJ, Lavery I, Yothers G, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937-3944, 2010
13. Kelley RK, Van Bebber SL, Phillips KA, et al: Personalized medicine and oncology practice guidelines: A case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw 9:13-25, 2011
14. Hutchins G, Southward K, Handley K, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261-1270, 2011
15. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
16. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
17. de la Chapelle A, Hampel H: Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28:3380-3387, 2010
18. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875, 2011
19. Clark-Langone KM, Sangli C, Krishnakumar J, et al: Translating tumor biology into personalized treatment planning: Analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 10:691, 2010
20. Ungefroren H, Groth S, Ruhnke M, et al: Transforming growth factor-beta (TGF-beta) type I receptor/ ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem 280:2644-2652, 2005
21. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250, 2003
22. Anjomshoaa A, Lin YH, Black MA, et al: Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer 99:966-973, 2008
23. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432:332-337, 2004
24. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
25. Garrity MM, Burgart LJ, Mahoney MR, et al: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 22:1572-1582, 2004
26. Kim H, Watkinson J, Varadan V, et al: Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics 3:51, 2010
27. Mesker WE, Junggeburt JM, Szuhai K, et al: The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29:387-398, 2007
28. Salminen E, Palmu S, Vahlberg T, et al: Increased proliferation activity measured by immunore-active Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 11:3245-3249, 2005
29. Niedzwiecki D, Bertagnolli MM, Warren RS: Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results of CALGB 9581. J Clin Oncol 29:3146-3152, 2011
30. Gray RJ: Weighted analyses for cohort sampling designs. Lifetime Data Anal 15:24-40, 2009
31. Bertagnolli MM, Niedzwiecki D, Compton CC, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814-1821, 2009
32. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 8:515-526, 1994
33. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2001
34. Verona EV, Elkahloun AG, Yang J, et al: Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res 67:5737-5746, 2007
35. Boman BM, Fields JZ, Cavanaugh KL, et al: How dysregulated colonic crypt dynamics cause stem cell overpopulation and initiate colon cancer. Cancer Res 68:3304-3313, 2008
36. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361:2449-2460, 2009
37. Cheng JD, Dunbrack RL Jr, Valianou M, et al: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62:4767-4772, 2002
38. Hofheinz RD, al-Batran SE, Hartmann F, et al: Stromal antigen targeting by a humanised monoclonal antibody: An early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26:44-48, 2003
39. Loeffler M, Krüger JA, Niethammer AG, et al: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116:1955-1962, 2006
40. Scott AM, Wiseman G, Welt S, et al: A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9:1639-1647, 2003
41. Welt S, Divgi CR, Scott AM, et al: Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 12:1193-1203, 1994
42. Neil JR, Johnson KM, Nemenoff RA, et al: Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 29:2227-2235, 2008
43. Berger DH, O’Mahony CA, Sheng H, et al: Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. Surgery 133:568-579, 2003
44. Carothers AM, Davids JS, Damas BC, et al: Persistent cyclooxygenase-2 inhibition downregu-lates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/ mouse model of colon tumorigenesis. Cancer Res 70:4433-4442, 2010
45. Sagiv E, Sheffer M, Kazanov D, et al: Gene expression following exposure to celecoxib in humans: Pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. Digestion 84:169-184, 2011
46. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009